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STAT3 is a key element inmanyoncogenic pathwaysand, like other transcription factors, is an
attractive target for development of novel anticancer drugs. However, interfering with STAT3
functionshas beenadifficult taskand very few smallmolecule inhibitorshavemade theirway
to the clinic. OPB-31121, an anticancer compound currently in clinical trials, has been reported
to affect STAT3 signaling, although its mechanism of action has not been unequivocally
demonstrated. In this study, we used a combined computational and experimental approach
to investigate the molecular target and the mode of interaction of OPB-31121 with STAT3. In
parallel, similar studies were performed with known STAT3 inhibitors (STAT3i) to validate
our approach. Computational docking and molecular dynamics simulation (MDS) showed
that OPB-31121 interacted with high affinity with the SH2 domain of STAT3. Interestingly,
there was no overlap of the OPB-31121 binding site with those of the other STAT3i. Computa-
tional predictions were confirmed by in vitro binding assays and competition experiments
alongwith site-directedmutagenesis of critical residues in the STAT3 SH2 domain. Isothermal
titration calorimetry experiments demonstrated the remarkably high affinity of OPB-31121 for
STAT3 with Kd (10 nM) 2e3 orders lower than other STAT3i. Notably, a similar ranking of the
potencyof the compoundswasobserved in termsof inhibitionofSTAT3phosphorylation, can-
cer cell proliferation and clonogenicity. These results suggest that thehighaffinity andefficacy
of OPB-31121 might be related to the unique features and mode of interaction of OPB-31121
with STAT3. These unique characteristics make OPB-31121 a promising candidate for further
development and an interesting lead for designing new, more effective STAT3i.
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 1 9 4e1 2 0 6 11951. Introduction to contribute to tumor initiation and progression in variousSignal Transducers and Activators of Transcription (STATs)
are a family of latent cytoplasmic proteins that once acti-
vated regulate many aspects of cell growth, survival and dif-
ferentiation (Levy and Darnell, 2002; Yu et al., 2009). The
main function attributed to STAT proteins is to act as signal
transducers and transcription factors with the ability to
transmit signals from the cell membrane to the nucleus
(Levy and Darnell, 2002; Yu et al., 2009). However, recent
studies have revealed a far more complex picture with a
range of novel and diverse functions associated with STAT
signaling both in the nucleus and other cell compartments
(Sehgal, 2008; Xu et al., 2007; Yu et al., 2014). The STAT family
includes seven members (STAT1, 2, 3, 4, 5a, 5b, and 6) that
share extensive structural homology (Yu et al., 2009). The
main structural motifs of STAT proteins are the N-terminal
domain (NTD), coiled-coil domain (CCD), DNA-binding
domain (DBD), Src Homology 2 domain (SH2) and C-terminal
domain (CTD). The NTD and CCD are required for nuclear
translocation and proteineprotein interaction, respectively
(Levy and Darnell, 2002; Lim and Cao, 2006). The DBD is
necessary for the recognition of specific DNA sequence ele-
ments and binding to gene promoters. The SH2 domain is
the most conserved domain of the family and is required
for formation of STAT3 dimers upon phosphorylation of spe-
cific tyrosine residues in the CTD of STAT proteins (Lim and
Cao, 2006; Zhong et al., 1994). In the case of STAT3 the key
event is the phosphorylation of tyrosine 705 (pY705). This
promotes the interaction between the SH2 domains of
distinct monomers and has been considered the main
pathway of activation of STAT3 signaling to the nucleus.
pY705 is induced by binding of cytokines and growth factors
to the respective receptors and consequent activation of the
receptor-associated tyrosine kinases, like Janus Kinases
(JAK) (Yu et al., 2009). Other non-receptor associated kinases,
such as Src, also activate nuclear STAT3 signaling through
the phosphorylation of Y705. Furthermore, in addition to
Y705 phosphorylation, STAT3 is phosphorylated at serine
727 (pS727) by various serine protein kinases (Zhang et al.,
1995). This modification has been reported to enhance the
STAT3 transcriptional activity (Wen et al., 1995) and, more
recently, to control mitochondrial localization and function
of STAT3 (Gough et al., 2009; Wegrzyn et al., 2009). Acetyla-
tion and methylation by protein acetyltransferases and
methyltransferases play also relevant roles in controlling
STAT3 functions in normal and pathological conditions
(Kim et al., 2013a; Lee et al., 2012; Yu et al., 2014; Yuan
et al., 2005). Furthermore, un-phosphorylated STAT3, present
both in the cytoplasm and nucleus, form dimers and has bio-
logical activity as transcription factor and signal transducer
independent of its phosphorylation status (Liu et al., 2005;
Sehgal, 2008; Timofeeva et al., 2012; Yang et al., 2007).
Alterations of the STAT3 signaling are associated with
different human diseases (O’Shea and Plenge, 2012). STAT3
is over-expressed and activated in many human cancers and
promotes cell proliferation, survival, tumor angiogenesis and
immune-evasion (Sansone and Bromberg, 2012; Yu et al.,
2009). Activation of the JAK/STAT3 pathway has been showncancer models (Yu et al., 2014, 2009). Recently, activation of
STAT3 has been associated with promotion and maintenance
of cancer stem-like cells (CSC), tumorigenicity and metastatic
capability in many human cancers, including prostate cancer
(Kroon et al., 2013; Marotta et al., 2011; Schroeder et al., 2014;
Yu et al., 2014). In many cancers activation of STAT3 is associ-
ated with advanced disease, metastasis and clinical progres-
sion (Sansone and Bromberg, 2012; Yu et al., 2009). The JAK/
STAT3 pathway contributes also to reduced response to treat-
ment promoting survival and development of resistance after
treatment with kinase inhibitors or, in prostate cancer, after
androgen deprivation therapy (Lee et al., 2014; Schroeder
et al., 2014; Sos et al., 2014). We have shown recently that acti-
vation of the JAK/STAT3 pathway contributes the establish-
ment of immune-tolerance and chemoresistance in a
prostate cancer mouse model through the secretion of immu-
nosuppressive cytokines in the tumor microenvironment
(Toso et al., 2014).
Over-activity of STAT3 in human cancers is frequently the
result of deregulation of upstream pathways leading to activa-
tion of cytokine and growth factor receptor associated tyro-
sine kinases, like JAK family kinases (Grivennikov and Karin,
2008; Sansone and Bromberg, 2012; Yu et al., 2014). Alternative
pathways controlling transcriptional and non-transcriptional
functions of STAT3 may have also important roles in
abnormal activation of STAT3 signaling in cancer (Meier and
Larner, 2014; Yu et al., 2014). In prostate cancer STAT3 has
been reported to induce cell transformation and tumor devel-
opment in the absence of pY705 (Qin et al., 2008). The onco-
genic effect of STAT3 in this system depended on pS727 and
transcriptional dependent and independent functions of
STAT3 (Qin et al., 2008). Acetylation and methylation are
also crucial for the role of STAT3 in the acquisition of cancer
stem cell-like phenotype and tumor progression (Kim et al.,
2013a; Su et al., 2011).
Because of its central role in multiple oncogenic pathways
and its diverse functions, STAT3 is an attractive target for
development of anticancer drugs and great effort has been
devoted over the last decade to the discovery of small mole-
cule inhibitors (Debnath et al., 2012; Miklossy et al., 2013; Yu
et al., 2009). Inhibitors of STAT3 can be classified as direct
and indirect inhibitors (Benekli et al., 2009; Debnath et al.,
2012). Indirect inhibitors interfere with cytokine and growth
factor receptors or upstream kinases that phosphorylate
STAT3. Conversely, direct inhibitors interact with the STAT3
protein and are expected to interfere with its multiple func-
tions (Debnath et al., 2012). Direct inhibitors can be divided
based on targeted protein domain, e.g. the NTD, DBD or SH2
domain. Due to its critical involvement in STAT3 activation,
the SH2 domain has been seen as the most attractive site
and SH2-targeting compounds constitute the largest class of
direct STAT3i (Debnath et al., 2012).
Genetic knockout, knockdown and small molecule inhibi-
tors of STAT3 have been shown to prevent tumor development
and growth in preclinicalmodels (Chan et al., 2004; Kortylewski
et al., 2005; Yu et al., 2009). However, despite the preclinical ev-
idence that STAT3 would be an ideal target for cancer therapy,
effective strategies to inhibit STAT3 in the clinic are still lacking
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culty of targeting directly transcription factors like STAT3.
Consequently, few direct STAT3i have shown relevant activity
in preclinical models in vivo and have been tested in clinical tri-
als (Debnath et al., 2012). OPB-31121 is a small molecule com-
pound that has been recently reported to interfere with
STAT3 signaling, although the underlying mechanism has
not been clarified yet (Hayakawa et al., 2013; Kim et al.,
2013b). OPB-31121 exhibits potent anticancer activity in vitro
and in tumor xenografts (Hayakawa et al., 2013; Kim et al.,
2013b) and is currently investigated in clinical trials (https://
clinicaltrials.gov). Understanding how OPB-31121 interacts
with STAT3 and themolecular basis of its potent anticancer ef-
fect would be highly relevant for further development of this
class of compounds. In this study, we combined in silico and
in vitro experiments to investigate how OPB-31121 and other
small molecule inhibitors interact with STAT3 and the func-
tional consequences of the drugetarget interaction. Impor-
tantly, our study reveals a unique mode of interaction of
OPB-31121 with the STAT3 SH2 domain not shared by any of
the other STAT3i tested. These unique features might be at
the basis of this compound’s efficacy and make OPB-31121 an
interesting lead for further development and design of new,
more effective STAT3i.2. Materials and methods
2.1. Computational studies
The crystal structures of STAT3 protein was obtained from
the available pdb file 1BG1 in the Protein Data Bank reposi-
tory (Becker et al., 1998). All compounds structures were
designed and optimized using Discovery Studio (DS, v. 2.5,
Accelrys Inc., San Diego, CA, USA) (Laurini et al., 2011). All
docking experiments were performed with Autodock 4.3
(Morris et al., 2009), with Autodock Tools 1.4.6 on a win64
platform following a consolidated procedure (Giliberti et al.,
2010). The binding free energy, DGbind, between each drug
and the protein was estimated resorting to the MM/PBSA
(Molecular Mechanics/Poisson-Boltzmann Surface Area)
approach. According to this well-validated methodology
(Laurini et al., 2012), the binding free energy was obtained
as the sum of the interaction energy between the receptor
and the ligand (DEMM), the solvation free energy (DGsol), and
the conformational entropy contribution (TDS), averaged
over a series of snapshots from the corresponding MDS tra-
jectories. The free energy of binding DGbind and the concen-
tration of ligand that inhibits the protein activity by 50%
(i.e., IC50) are related by the following fundamental equation:
DGbind ¼ RT ln 1/IC50, where R is the gas constant and T is
the temperature. Thus, once DGbind for a given protein/inhib-
itor couple is estimated by MM-PBSA simulations, the relative
IC50 value is also known by virtue of this relationship. The
role of the key residues identified by PRBFED was further
studied by performing computational alanine scanning
(CAS) experiments (Guo et al., 2012). Accordingly, the abso-
lute binding free energy of each mutant protein, in which
one of the key residue was replaced with alanine, wascalculated with the MM/PBSA method and corresponded to
the difference in the binding free energy between the wild-
type (wt) and its alanine mutant (mut) counterpart.
2.2. Cell lines, plasmids, chemicals and antibodies
Human prostate cancer DU145 and LNCaP cell lines were pur-
chased from American Type Culture Collection and main-
tained in RPMI supplemented with 10% (FBS) (PAA,
Brunschwig, Basel, CH). STAT3 SH2 domain (amino acid resi-
dues 586e685) was subcloned into pGEX-2T vector (GE Health-
care Europe GmbH) from pET28a-STAT3-SH2 domain
(GenScript USA Inc) using BamHI and EcoRI restriction sites.
Mutant constructs were generated using GENEART Site-
Directed Mutagenesis System (Life Technologies). OPB-31121
(Otsuka Pharmaceutical, Tokyo, Japan), STA-21, and Stattic
(ENZO LIFE SCIENCES AG, Lausen, CH), S31.201 and Cryptotan-
shinone (Merck KGaA, VWR, Dietikon, CH) were dissolved in
DMSO. IL-6 (10 ng/ml, R&D Systems Europe Ltd., Abingdon,
UK), ampicillin (50 mg/ml, Eurobio) and IPTG (isopropyl-b-D-thi-
ogalactopyranoside, 1 mM, Promega, D€ubendorf, CH) were
dissolved in sterile water. Antibodies against STAT3, pSTAT3
Tyr705, pSTAT3 Ser727, were purchased from Cell Signaling
Technology (BIOCONCEPT, Allschwil, CH), and GAPDH from
Millipore (Zug, CH).
2.3. Western blotting
Cells were washed once in PBS and lysed in lysis buffer
(25 mM TriseHCl pH ¼ 7.4, 50 mM KCl, 5 mM EDTA, 1%
NP-40, 0.5% Sodium deoxycholate, 0.1% SDS) supplemented
with protease and phosphatase inhibitors cocktail (Roche
Diagnostics (Schweiz) AG, Rotkreuz, CH), sodium orthovana-
date (Na3VO4, Acros Organics) and phenylmethanesulfonyl-
fluoride (PMSF, SigmaeAldrich). After 20 min of incubation
on ice samples were centrifuged for 15 min at 4 C and pro-
teins were quantified using BCA Protein Assay Kit (Pierce,
Perbio Science Switzerland SA, Lausanne, CH). Proteins
were loaded on 10e12% Sprint Next Gel (Amresco, Bio-
concept, Allschwil CH) and analyzed by immunoblotting.
Membranes were blocked for 1 h with 0.2% of I-Block (Life
Technologies) and then probed overnight at 4 C with pri-
mary antibodies and for 1 h with horseradish peroxidase
(HRP)-conjugated secondary antibodies. Western Bright
ECL detection system (WITEC AG, Littau, CH) was used for
detection.
2.4. Cell viability
DU145 and LNCaP cells were plated in 96-well plates in phenol
red-free RPMI supplemented with 10% serum. After 24 h cells
were treatedwith the indicated STAT3 inhibitors. Cell viability
was determined using MTT assay after 72 h (Genini et al.,
2012). All assays were performed in triplicate and repeated
in at least three independent experiments.
2.5. Colony forming assay
Cells were plated in triplicate in 6-well plates. Drugs were
added to the medium at increasing concentrations. After 10
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ethanol. Colonies were counted with an automated colony
counter Alphaimager 3400 (Napoli et al., 2009). Results are rep-
resented as mean  SD from 3 independent experiments.2.6. Expression and purification of GST-STAT3 SH2
domain
Escherichia coli strain BL21(DE3) (Life Technologies) trans-
formed with the pGEX-2T-GST-STAT3-SH2 domain plasmids
(WT, S636A, and V637A mutants) or pGEX-2T-GST (100 ng of
DNA) was grown at 37 C in LB medium containing ampi-
cillin (50 mg/ml) to an OD 600 of 0.6e0.7. Cells were then
induced with 1 mM IPTG for 4 h at 37 C and subsequently
harvested by centrifugation at 4000  g. The bacterial pellet
was resuspended in cold PBS containing protease inhibitors
plus 1 mg/ml of lysozyme (SigmaeAldrich) and sonicated
(30 s of pulsing/30 s of pause for 6 times). Triton X-100 (Sig-
maeAldrich) was then added at a final concentration of 1%
and the lysate was centrifuged for 20 min at 4 C. Superna-
tant was filtered (0.45 mm), diluted 1:1 with cold PBS and pu-
rified by affinity chromatography using GSTrap HP column
(GE Healthcare). Fusion proteins were eluted with 10 mM
of glutathione, reduced, desalted in PBS and concentrated
to 1 mg/ml.2.7. Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments of STAT3i
binding to the STAT3 SH2 domain were conducted with a
Nano ITC Technology (TA Instruments) at 25 C. After tem-
perature equilibration, GST-SH2-WT, GST-SH2/S636A or GS-
SH2/V637A mutant protein solutions (10m M) were titrated
with each inhibitor (100 mM in 1% v/v DMSO) by adding 1 mL
of compound solution to the protein solution at intervals of
4 min. The titration of a GST-SH2 domain in PBS solution
containing 1% DMSO v/v with the same inhibitor solutions
was used as blank test and to determine the heat of dilution
of ligand. This reference experiment, carried out in the same
way as the titration with protein sample, was subtracted
from the sample data. The corrected binding isotherms
were fitted to yield the values of the binding constant (Kd),
the stoichiometry (n), and the binding enthalpy (DH) of each
STAT3 SH2 domain/inhibitor binding event. Once the Kd for
each inhibitor/protein was determined, the corresponding
free energy of binding DGbind and the IC50 values were ob-
tained via the above mentioned relationship: DGbind ¼ RT
ln Kd ¼ RT ln 1/IC50.2.8. Circular dichroism
CD spectra from GSH-SH2-WT, GST-SH2/S636A or GST-SH2/
V637A mutants (0.1 mg/ml in 10 mM NaPO4, pH 7.4) were
recorded on a Chirascan spectropolarimeter (Applied Photo-
physics) over the wavelength range from 195 to 260 nm at a
band width of 1 nm, step size of 0.5 nm and 1s per step. The
spectra in the far-ultraviolet region required an average of
five scans and were subtracted from blank spectra per-
formed with GST in buffer.3. Results
3.1. In silico analysis of the binding of OPB-31121 to
STAT3
We used various computational approaches to examine in sil-
ico the binding of OPB-31121 (Hayakawa et al., 2013; Kim et al.,
2013b) to STAT3 (Figure 1A). For comparison we used in our
analyses selected STAT3i, like STA-21 (Song et al., 2005), Stat-
tic (Schust et al., 2006), S3I.201 (Siddiquee et al., 2007) and
Cryptotanshinone (Shin et al., 2009), for which there was pre-
vious evidence of interaction with the STAT3 SH2 domain.
OPB-31121 was docked onto the SH2 domain and then the
relevant drug/protein affinities were scored by molecular dy-
namics simulation (MDS) (Figure 1B). Using the same
approach these parameters were determined for all the other
STAT3i (Figure S1). In the case of Stattic, which is able to form
covalent crosslinks with STAT3 (Schust et al., 2006), we
considered only the initial step of non-covalent interaction.
Table 1 and Table S1 show the values of the calculated IC50,
free energy of binding DGbind and the enthalpic and entropic
components predicted for the interaction of each compound
with the STAT3 SH2 domain obtained from these in silico ana-
lyses. The calculated IC50 value for OPB-31121 was in the low
nanomolar range (IC50,w18 nM). Notably, this valuewas about
2e3 orders of magnitude lower than the IC50 estimated for the
other STAT3i (ranging from 1.4 to 27.2 mM).
To understand the basis of the remarkable high affinity of
OPB-31121 for STAT3 we performed a per-residue deconvolu-
tion analysis of the free energy of binding (Figure 1C). The
resulting interaction spectrum showed that the residues
mostly involved in the binding of the drug clustered in two re-
gions of the SH2 domain. Region 1 included residues from
Q635 to E638 and region 2 included residues from T714 to
T717. In addition, other four residues (i.e., W623, K626, I659,
and V667) were found to be engaged inmajor stabilizing inter-
actions with OPB-31121. The same procedure was applied to
the other STAT3i leading to the definition of the STAT3 inter-
action spectrum for each of the compounds (Figure S1EeH).
Interestingly, the interaction spectra were compound-
specific with very little, if any, overlap between them. More-
over, the interaction region defined for OPB-31121 was clearly
distinct from those of all the other STAT3i. A visual represen-
tation of these results is given in Figure 1D, where each drug/
STAT3 interaction surface is represented in a different color.
Thus, our in silico data indicated that OPB-31121 bound with
remarkably high affinity to STAT3 and interacted with a
distinct pocket in the SH2 domain with different residue spec-
ificity compared to other STAT3i.3.2. In vitro assessment of the binding of OPB-31121 to
the STAT3 SH2 domain
The binding of OPB-31121 to the SH2 domain of STAT3 was
next investigated using recombinant GST-tagged STAT3 SH2
domain and isothermal titration calorimetry (ITC). Consistent
with the in silico data, ITC demonstrated high affinity binding
of OPB-31121 to the STAT3 SH2 domain yielding an experi-
mental Kd of 10 nM (Figure 2A). We assessed the binding of
Figure 1 e In silico binding of OPB-31121 to STAT3. (A) Three-dimensional structure of the STAT3 protein. The different domains of STAT3
are indicated in different colors indicated both in the structure and diagram. (B) Details of the binding site of OPB-31121 in the STAT3 SH2
domain obtained from equilibrated MDS snapshots. The protein backbone is portrayed as a transparent sky blue ribbon; the main residues
involved in drug interactions are shown as labeled colored sticks. OPB-31121 is portrayed as atom-colored sticks-and-balls. (C ) Interaction
spectrum for STAT3 in complex with OPB-31121. Only residues for which DGbind is ‡ 0.75 kcal/mol are shown. (D) Binding pockets of different
inhibitors on the STAT3 SH2 domain highlighted by their respective van der Waals surfaces. Dark gray, SH2 domain; blue, OPB-31121; yellow,
STA-21; red, cryptotanshinone; green, S3I.201. Stattic is hidden by cryptotanshinone that binds to an overlapping site.
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dicted by the in silico analysis, S3I.201 also bound to the SH2
domain but with a substantially lower affinity compared to
OPB-31121 (Kd ¼ 8 mM) (Figure 2B). All other STAT3i showed
similar low binding affinities with experimental Kd in the
micromolar range (Figure S2). Notably, the data from in vitro
binding assays were in good agreement with the estimated
IC50 values determined by MDS (Table 1). Control ITC experi-
ments were conducted with recombinant GST to rule out
non-specific binding of the compounds. None of tested com-
pounds showed any interaction with GST (Figure S3). Hence,
the in vitro binding assays supported the computational chem-
istry prediction of high affinity binding of OPB-31121 to the
STAT3 SH2 domain.
The in silico analyses predicted also a distinct binding site
for OPB-31121 in the STAT3 SH2 domain compared to other
STAT3i. In order to test the reliability of this prediction weperformed competition assays with OPB-31121 and S3I.201.
The recombinant GST-tagged STAT3 SH2 domain was incu-
bated first with a saturating concentration of S3I.201 and
then titrated with increasing concentrations of OPB-31121
(Figure 2C). OPB-31121 binding was similar in the presence
and absence of S3I.201 yielding similar Kd values in both con-
ditions. Thus, these data confirmed the in silico prediction of
the existence of independent, non-overlapping binding
pockets for OPB-31121 and other STAT3i in the STAT3 SH2
domain.
3.3. In silico alanine scanning and in vitro site-directed
mutagenesis analysis of the OPB-31121 binding site
To further validate the predicted binding site of OPB-31121 we
selected two residues (S636 and V637) in the drugetarget
interaction region of the STAT3 SH2 domain defined by
Table 1 e Predicted free energy of binding (DGbind) and IC50 values for OPB-31121, Cryptotanshinone, STA-21, S3I.201, and Stattic in complex
with STAT3.
OPB-31121 STA-21 Stattic Crypto S3I.201
DGbind (kcal/mol) 10.54  0.77 6.47  0.88 6.99  0.79 8.01  0.61 6.23  0.89
IC50 (mM)
a 0.0187 17.900 7.400 1.400 27.200
a DGbind and IC50 of ligand are related by the following fundamental equation: DGbind ¼ RT ln 1/IC50, where R is the gas constant and T is the
temperature. Once DGbind for a given protein/ligand couple is estimated byMM-PBSA simulations, the relative IC50 value is determined by virtue
of this relationship.
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residueswas first tested in silico by alanine scanningmutagen-
esis (Figure 3AeB). Turning either the S636 or V637 residue
into alanine affected the positioning of OPB-31121 in theFigure 2 e In vitro binding of OPB-31221 to the STAT3 SH2
domain. (A) Isothermal titration calorimetry (ITC) data for the
STAT3 SH2 domain/OPB-31121 system. (B) ITC data for the
STAT3 SH2 domain/S3I.201 system. (C ) ITC analysis of OPB-
31121 interaction with the STAT3 SH2 domain after pre-incubation
with S3I.201.binding pocket and greatly reduced the binding affinity result-
ing in a dramatic increase in the estimated IC50 values from
18 nM to 5 mM and 1.1 mM for S636A and V637A, respectively
(Table 2). As proof of the specificity, we applied the same
approach to S3I.201. Consistent with a distinct interaction
site, neither the S636A nor V637A mutation affected signifi-
cantly the binding mode and the estimated binding affinity
of S3I.201 (Figure 3CeD and Table 2).
In parallel with the in silico studies, we performed in vitro
site-directed mutagenesis for the same residues and assessed
binding to wild type and mutated GST-tagged STAT3-SH2
domain by ITC. Correct folding of the mutated SH2 domains
was determined by comparing circular dichroism (CD) spectra
of thewild-type andmutant protein (Figure S4). Bothwild type
and mutant SH2 domains displayed the typical SH2 spectra
indicating that the mutations did not affect the native confor-
mation of the protein. However, the presence of the S636A or
V637Amutation abrogated binding of OPB-31121 in ITC exper-
iments, sustaining the validity of the computational model
(Figure 3EeF). Interestingly, the binding of the reference com-
pound S3I.201 to the STAT3 SH2 domain was not affected by
either mutation, showing affinities similar to that for the
wild-type protein (Figure 3GeH).3.4. Inhibition of Y705 and S727 STAT3
phosphorylation by OPB-31121
To assess the biological activity of OPB-31121 we assessed its
ability to interfere with STAT3 phosphorylation in human
prostate cancer cells. Direct STAT3i may expect to block the
interaction of STAT3 with protein kinases and likely prevent
phosphorylation at Y705. In these assayswe used two prostate
cancer cell lines that exhibited constitutive (DU145) and IL-6
inducible (LNCaP) Y705 phosphorylation, respectively. Cells
were treated with increasing concentrations of OPB-31121
for 16 h. LNCaP cells were stimulated with IL-6 during the
last 30 min of the incubation to induce pY705. OPB-31121 at
doses of 5e10 nM almost completely blocked pY705 in both
cell lines (Figure 4AeB). We assessed the kinetics of pY705 in-
hibition using a dose of 10 nM of OPB-31121. Incubation with
OPB31121 for 4e8 h completely abrogated pY705 in both cell
lines (Figure 4CeD). We assessed next the effect of OPB-
31121 on pS727, which in both DU145 and LNCaP cells is
constitutively phosphorylated. Interestingly, OPB-31121
reduced pS727 with dose dependence and kinetics similar to
those observed for pY705 inhibition in both cell lines
(Figure 4AeD). We noticed also a decrease of total STAT3 pro-
tein level in cells treated with OPB-31121 at high concentra-
tions (50 nM) and for longer incubation times (16 h).
Figure 3 e Mutational analysis of OPB-31121 binding site in the STAT3 SH2 domain. (A) Superposition of the binding site of wild type (light
blue) and S636A STAT3 mutant (orange) in complex with OPB-31221. (B) Superposition of the binding site of wild type (light blue) and V637A
STAT3 mutant (golden rod) in complex with OPB-31221. (C ) Superposition of the binding site of wild type (aquamarine) and S636A STAT3
mutant (sandy brown) in complex with S3I.201. (D) Superposition of the binding site of wild type (aquamarine) and V637A STAT3 mutant
(salmon) in complex with S3I.201. In all panels drugs are depicted as colored sticks-and-balls, while main residues involved in the interactions are
labeled and shown as colored sticks. Hydrogen atoms, water molecules, ions and counterions are omitted for clarity. (E ) ITC data for S636A
mutant STAT3 SH2 domain in complex with OPB-31121. (F ) ITC data for V637A mutant STAT3 SH2 domain in complex with OPB-31121;
(G) ITC data for S636A mutant STAT3 SH2 domain in complex with S3I.201; (H ) ITC data for V637A mutant STAT3 SH2 domain in complex
with S3I.201.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 1 9 4e1 2 0 61200We performed similar experiments with the other STAT3i.
All the compounds inhibited pY705 (Figure 5A). However, even
for the most potent of these compounds (Cryptotanshinone)
doses  5 mM were needed to significantly affect pY705.
S3I.201, STA-21 and Stattic were active at doses 20 mM toinhibit pY705 to a comparable level. Notably, these differences
in potency reflected closely the differences in the binding af-
finity between OPB-31121 and the other STAT3i. Interestingly,
when we examined the kinetics of inhibition of pY705 and
pS727 by cryptotanshinone and S3I.201 a reduction of pY705
Table 2 e Predicted free energy of binding (DGbind), binding energy difference DDGbind[ DGbind(wild type) eDGbind(mutant), and IC50 values
for OPB-31121 and S3I.201 with S636A and V637A STAT3 mutants.
S636A V637A
OPB-31121 S3I.201 OPB-31121 S3I.201
DGbind (kcal/mol) 7.23  0.64 6.15  0.67 8.11  0.69 6.26  0.78
DDGbind (kcal/mol) 3.31 0.08 2.43 þ0.03
IC50 (mM) 5 31.2 1.1 25.9
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 1 9 4e1 2 0 6 1201was seen within 4 h (Figure S5AeB). However, significant inhi-
bition of pS727 required longer incubation time (8e16 h). As
seen with OPB-31121, most of these compounds induced
also a decrease of total STAT3 level at the highest doses tested.
Although the cause of the reduction of total STAT3 needs to be
investigated, this could be a consequence of the continuous
presence of high concentrations of the inhibitors in cells inter-
fering the synthesis or degradation of STAT3 protein at the
transcriptional or post-transcriptional level.
Collectively, these experiments showed that OPB-31121
reduced effectively both pY705 and pS727. OPB-31121 acted
at low doses andwithin few hours of incubation on both phos-
phorylation events. The activity of OPB-31121 was not influ-
enced by the preexisting phosphorylation status of Y705 and
similar effects were seen in cells with constitutive and induc-
ible phosphorylation at this site. Notably, in these cellular as-
says OPB-31121was about 100e1000 foldmore potent than the
other STAT3i tested here, in line with the high binding affinity
for STAT3 demonstrated in vitro by this compound.
3.5. Antiproliferative activity of OPB-31121 in prostate
cancer cells
Our data showed that OPB-31121was highly effective in block-
ing both pY705 and pS727 in DU145 and LNCaP prostate cancer
cell lines. Increased STAT3 levels and higher Y705 and S727Figure 4 e Inhibition of STAT3 phosphorylation at Y705 and S727 by OPB
cells treated with the indicated concentrations of OPB-31121 for 16 h (Ce
incubated with OPB-31121 (10 nM) and analyzed at the indicated times. IL
to induce pY705.phosphorylation are frequent in human prostate cancer at
the early (androgen-dependent) and late (castration-resistant)
stages of the disease (Culig et al., 2005; Dhir et al., 2002; Mora
et al., 2002). Activation of STAT3 signaling in prostate cancer is
generally associated with poor clinical outcome (Culig et al.,
2005; Dhir et al., 2002; Mora et al., 2002). Thus, the availability
of a compound that could directly and effectively block STAT3
signaling through multiple downstream pathways could be
highly advantageous in prostate cancer. OPB-31121 has been
reported to be active in preclinical models of various human
cancers (Hayakawa et al., 2013; Kim et al., 2013b). However,
the compound has never been tested in prostate cancer cells.
Hence, we assessed the effects of OPB-31121 on the viability
and proliferation of LNCaP and DU145 cells, which are com-
mon models of androgen-dependent and castration-
resistant prostate cancer, respectively. OPB-31121 inhibited
proliferation of both LNCaP and DU145 cells with IC50 values
in the nanomolar range (18 and 25 nM) (Figure 6A). Colony for-
mation was also strongly inhibited by OPB-31121 at doses of
10e50 nM (Figure 6B). Interestingly, OPB-31121 was effective
in unstimulated LNCaP cells in line with the notion that the
drug’s activity was independent of the Tyr705 phosphoryla-
tion status. For comparison we tested the effects of the other
STAT3i in the same cell lines. All the compounds affected cell
proliferation, but the doses required to achieve significant
levels of inhibition were considerably higher than those of-31121. (AeB) STAT3 phosphorylation in DU145 (A) and LNCaP (B)
D) STAT3 phosphorylation in DU145 (C ) and LNCaP (D) cells
-6 was added for 30 min at the end of the treatment with OPB-31121
Figure 5 e Inhibition of STAT3 phosphorylation at Y705 by STA-21, Stattic, Cryptotanshinone, and S3I.201 for 16 h in DU145 (A) and LNCaP
(B) cells.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 1 9 4e1 2 0 61202OPB-31121 (Figure 6A). Higher doses of these STAT3i were also
required in the clonogenic assays (Figure 6B). Thus, in line
with the higher binding affinity, OPB-31121 was substantially
more potent in suppressing cell proliferation and colony for-
mation compared to other STAT3i.4. Discussion
STAT3 is a latent cytoplasmic protein whose multiple func-
tions are controlled by various post-translational modifica-
tions (Yu et al., 2014, 2009). Phosphorylation at Y705 and
S727 have been reported to enhance nuclear localization and
transcriptional activity of STAT3. pS727 controls also mito-
chondrial functions of STAT3 (Levy and Darnell, 2002; Yu
et al., 2014, 2009). Furthermore, un-phosphorylated STAT3 is
not devoid of biological activity and exerts both transcrip-
tional and non-transcriptional functions (Timofeeva et al.,
2012; Yang et al., 2007). Because of its involvement in multiple
biological pathways, STAT3 has an important role in human
cancers sustaining neoplastic transformation and promoting
tumor progression (Yu et al., 2014, 2009). Therefore, there is
high interest in developing direct STAT3i that might interfere
with the multiple and diverse functions of this pleiotropic
transcription factor (Debnath et al., 2012). OPB-31121 has
been recently reported to inhibit STAT3 signaling and has rele-
vant anticancer activity in preclinical models in vitro andin vivo (Hayakawa et al., 2013; Kim et al., 2013b). Based on its
efficacy in preclinical models, phase I/II clinical trials have
been initiated with this compound (Hayakawa et al., 2013;
Kim et al., 2013b). Results from a first phase I study in patients
with advanced solid tumors indicate that the drug orally
administered was well tolerated and had a favorable toxicity
profile, but low bioavailability and unfavorable pharmacoki-
netics impair its use in the clinic (Bendell et al., 2014). More-
over, despite the proven efficacy in preclinical models,
questions remain about the intracellular target and mecha-
nism of action of OPB-31121 (Hayakawa et al., 2013; Kim
et al., 2013b). In light of the recent preclinical and clinical
data, this informationwould be highly valuable for continuing
its development and generating new inhibitors with improved
activity and pharmacological profile. In this study, we com-
bined computational and experimental approaches to define
themode of interaction of OPB-31121with STAT3. For compar-
ison, we performed similar studieswith a series of structurally
distinct STAT3i. To our knowledge, a detailed study of how
different small molecules interact with the SH2 domain of
STAT3 and how their binding mode impact on the biological
activity of the compounds is missing. Indeed, even slight dif-
ferences in the interaction site and binding affinity might be
highly relevant in terms of biological activity and potency of
the compounds. Interestingly, we found that OPB-31121 has
a remarkably high affinity for STAT3 and unique mode of
interaction with the SH2 domain compared to other STAT3i.
Figure 6 e Inhibition of cell proliferation and colony formation by
STAT3 inhibitors. (A) Cell viability determined by MTT assay in
DU145 and LNCaP cells incubated with the indicated compounds.
Left, IC50 values for each compound in the two cell lines. (B)
Anchorage-dependent clonal growth of DU145 and LNCaP cells
treated with the indicated doses of OPB31121, STA-21, Stattic,
cryptotanshinone, and S3I.201. *P< 0.01.
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examine the potential binding site of OPB-31121 in the SH2
domain of STAT3. The residues in the SH2 domain lining the
putative binding site were identified and those affording ma-
jor stabilizing contributions were investigated by free energy
deconvolution and in silico alanine scanning mutagenesis.
The same computational procedure was applied to the other
STAT3i with the purpose of a direct comparison of binding
modes and sites of interaction. Importantly, the computa-
tional predictions were validated by in vitro binding assaysusing ITC and purified STAT3 SH2 domain. Both series of ex-
periments concurred to show that OPB-31121 binds to STAT3
in the SH2 domain with very high affinity. Notably, both the
computationally and experimentally estimated Kd values for
OPB-31121 were 2e3 orders of magnitude lower than those
of the other STAT3i tested in this study. A similar ranking of
the compounds was obtained in the cellular assays based on
their efficacy on STAT3 phosphorylation and cell proliferation.
All the data confirmed the substantially higher potency of
OPB-31121 compared to the other STAT3i.
In greater details, our in silico analysis identified two
distinct binding pockets for small molecule inhibitors in the
SH2 domain of STAT3: the first was occupied by OPB-31121
and the second was common to all the other inhibitors
(Figure 1D). The crystal structure of the STAT3-SH2 domain re-
veals the existence of one hydrophilic and two hydrophobic
sub-pockets (Becker et al., 1998). Most STAT3i are predicted
to bind either to the hydrophilic site, lined by the side chains
of the K591, R609, S611, and S613 residues, or to the partially
hydrophobic region composed by the K592, R595, I597, and
I634 residues (Fletcher et al., 2008). Our computational ana-
lyses confirmed that all four STAT3i considered here (i.e.,
cryptotanshinone, STA-21, Stattic, and S3I-201) fit in these
two sub-pockets (Figure 1D and Figure S1). In contrast, OPB-
31121 was found to bind to a distinct region that included
the third, hydrophobic sub-pocket (Figure 1BeC). Further-
more, OPB-31121 interacted with a consistently larger number
of residues in the SH2 domain compared to the other com-
pounds; this in turn contributed to the higher affinity of
OPB-31121 for STAT3, as indicated by the extremely favorable
comparison of estimated IC50 (Table 1) and Kd values
(Figure 2A). The ITC experiments concurred to support the in
silico model of interaction of OPB-31121 with the STAT3 SH2
domain. Competition experiments and site-directed muta-
genesis showed the specificity of the identified interaction
site in the SH2 domain for OPB-31121 (Figures 2e3).
The presence of a distinct sub-pocket and the high binding
affinity of OPB-31121 explain in part the high efficacy of the
compound in inhibiting STAT3 phosphorylation in cells.
Furthermore, in the case of OPB-31121 inhibition of pY705
and pS727 occurred at similar doses and within the same
time scale (w4 h) (Figure 4). This was not the case with other
STAT3i, like cryptotanshinone and S3I.201, for which the inhi-
bition of pS727 was delayed with respect to pY705 inhibition
(Figure S5). Thus, occupying a wider and distinct area in the
SH2 domain, OPB-31121 could impair more effectively the
interaction of STAT3 with kinases and other proteins and pre-
vent simultaneously and with higher efficiency phosphoryla-
tion of these residues compared to other STAT3i. Collectively,
our results demonstrate that OPB-31121 binds to the SH2
domain and interferes directly with STAT3 activation and
signaling. Higher affinity for the target likely leads to higher
potency in cellular assays and in vivo, although the com-
pound’s propensity to be internalized in cells andmetabolized
could influence its efficacy in biological systems.
Interfering with JAK/STAT3 signaling has been recently
proposed as a valid option for treatment of cancer, including
prostate cancer (Hedvat et al., 2009; Kroon et al., 2013;
Schroeder et al., 2014). However, based on the current under-
standing of the multiple functions and diverse activation
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 1 9 4e1 2 0 61204modes of STAT3, blocking pY705 alone may not be sufficient.
Alternatively post-translationally modified as well as un-
phosphorylated STAT3 are emerging as important mediators
of STAT3 signaling in normal and cancer cells (Yu et al.,
2014), emphasizing the need of compounds that could interact
and interfere directly with STAT3. For instance, pS727 is
frequently increased in prostate cancer and has been shown
to be sufficient to drive prostate tumorigenesis and progres-
sion independently of pY705 (Qin et al., 2008). Furthermore,
in preclinical models of prostate cancer inactivation of
pS727 is sufficient to substantially reduce tumorigenicity
(Qin et al., 2008). Therefore, in line with the prominent activa-
tion of STAT3 signaling in prostate cancer (Culig et al., 2005;
Dhir et al., 2002; Mora et al., 2002), we tested the activity of
OPB-31121 in LNCaP and DU145 prostate cancer cell lines
representative of androgen-dependent and castration-
resistant tumors, respectively. We found that OPB-31121 was
a potent inhibitor of proliferation and clonogenicity in both
cellmodels (Figure 6). Interestingly, the antiproliferative effect
of OPB-31121was independent of the pY705 status and related
to its high affinity for the target and ability to block effectively
and concomitantly both pY705 and pS727. This raises the pos-
sibility that the efficacy of OPB-31121 may not depend exclu-
sively on the Y705 phosphorylation status and additional
factors should be taken in consideration to identify potentially
sensitive tumor types. Together, these findings suggest that
the use of direct STAT3i like OPB-31121 could be expanded
to tumors that harbor not only constitutive pY705 but addi-
tional biomarkers (e.g., total and pS727 STAT3 level) should
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